New study tracks Long-Term safety of muscle stiffness drug namuscla
NCT ID NCT04616807
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study followed 53 adults with non-dystrophic myotonic disorders who were taking Namuscla (mexiletine) to manage muscle stiffness. Researchers monitored side effects and how often patients needed to reduce their dose or stop treatment over up to 36 months. The goal was to see if the drug remains safe and effective with long-term use.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Mexiletine (Namuscla)
What this could lead to
If successful, this study could confirm that Namuscla is safe and effective for long-term use in managing muscle stiffness.
What could go wrong
This is an observational study, not a controlled trial, so results may be less reliable. It only includes 53 participants, and side effects or lack of effectiveness could still occur.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYOTONIC DYSTROPHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHRU Lille
Lille, 59000, France
-
Hôpital Universitaire de La Pitié Salpêtrière
Paris, Cedex, 13 75013, France
-
Institute of Neurology
London, England, WC1N 3BG, United Kingdom
-
Nottingham University Hospitals NHS Trust
Nottingham, England, NG7 2UH, United Kingdom
-
St. Josef-Hospital Klinikum der Ruhr Universitaet Bochum
Bochum, North Rhine-Westphalia, 44791, Germany
-
Universitätsklinikum Ulm, Klinik für Neurologie
Ulm, 89081, Germany